Oral R115866 in the treatment of moderate to severe plaque-type psoriasis

Journal of the European Academy of Dermatology and Venereology

Volumn 21, Issue 8, 2007, Pages 1038-1046

  Verfaille, C J ^a,d   Thissen, C A C B ^b   Bovenschen, H J ^c   Mertens, J ^d   Steijlen, P M ^a,b   Van De Kerkhof, P C M ^c  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Barrier Therapeutics   (Belgium)

Author keywords

4 hydroxylase inhibitor; Psoriasis; R115866; Rambazole ; Retinoic acid; Retinoic acid metabolism blocking agent

Indexed keywords

DERMATOLOGICAL AGENT; N [4 [2 ETHYL 1 (1H 1,2,4 TRIAZOL 1 YL)BUTYL]PHENYL] 2 BENZOTHIAZOLAMINE; RAMBAZOLE; RETINOIC ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHEILITIS; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; ECG ABNORMALITY; EPISTAXIS; FEMALE; FOLLOW UP; HAIR LOSS; HEART ATRIUM FIBRILLATION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTRIGLYCERIDEMIA; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; PSORIASIS VULGARIS; RATING SCALE; SIDE EFFECT; SKIN EXAMINATION; SKIN FRAGILITY; SKIN PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; XEROSIS; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; AGED; BENZOTHIAZOLES; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; TRIAZOLES;

EID: 34548160458     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2007.02158.x     Document Type: Article

References (34)

1. Stoppie P, Borgers M, Borghgraef P et al. R115866 Inhibits all-trans -retinoic acid metabolism and exerts retinoidal effects in rodents. J Pharmacol Exp Ther 2000; 293: 304-312.
2. Stoppie P, Van Wauwe J, Wouters L et al. Rambazole™, a potent inhibitor of all- trans -retinoic acid metabolism, applied topically to mouse tail skin exerts retinoid mimetic activity. J Invest Dermatol 2004; 122: A70 (#420).
3. Asselineau D, Darmon M. Retinoic acid provokes metaplasia of epithelium formed in vitro by adult human epidermal keratinocytes. Differentiation 1995; 58: 297-306.
4. Kopan R, Traska G, Fuchs E. Retinoids as important regulators of terminal differentiation examining keratin expression in individual epidermal cells at various stages of keratinization. J Cell Biol 1987; 105: 427-440.
5. Napoli JL. Retinoic acid. its biosynthesis and metabolism. Prog Nucleic Acid Res Mol Biol 1999; 63: 139-188.
6. Petkovich PM. Retinoic acid metabolism. J Am Acad Dermatol 2001; 45: S136-S142.
7. Cools M, Stoppie P, Cauwenbergh G et al. Tolerability, safety and pharmacokinetics of single and multiple oral dosages of R115866 (Rambazole™) in healthy volunteers. Presented at the 15th meeting of the European Academy of Dermatology and Venereology, 4-7 October 2006, Rhodos, P035.22.
8. Barrier Therapeutics. Rambazole™ (R115866) Investigational Drug Brochure, Version 3. 60; October 2005. Data on file. Barrier Therapeutics, Geel, Belgium.
9. Hartman S, Brors O, Bock J et al. Exposure to retinyl esters, retinol and retinoic acids in non-pregnant women following increasing single and repeated oral doses of vitamin A. Ann Nutr Metab 2005; 49: 155-164.
10. Tang G, Russell RM. 13-cis Retinoic acid is an endogenous compound in human serum. J Lipid Res 1990; 31: 175-182.
11. Wiegand U-W, Chou RC. Pharmacokinetics of oral isotretinoin. J Am Acad Dermatol 1998; 39: S8-S12.
12. Napoli JL, Pramanik BC, Williams JB et al. Quantification of retinoic acid by gas-liquid chromatography-mass spectrometry: Total versus all-trans-retinoic acid in human plasma. J Lipid Res 1985; 26: 387-392.
13. Dockx P, Decree J, Degreef H. Inhibition of the metabolism of endogenous retinoic acid as treatment for severe psoriasis: An open study with oral liarozole. Br J Dermatol 1995; 133: 426-432.
14. Berth-Jones J, Todd G, Hutchinson PE et al. Treatment of psoriasis with oral liarozole: A dose-ranging study. Br J Dermatol 2000; 143: 1170-1176.
15. Bhushan M, Burden AD, McElhone K et al. Oral liarozole in the treatment of palmoplantar pustular psoriasis: A randomized, double-blind, placebo-controlled study. Br J Dermatol 2001; 145: 546-553.
16. Gollnick H, Bauer R, Brindley C et al. Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German Multicenter study. J Am Acad Dermatol 1988; 19: 458-469.
17. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244.
18. Weinstein GD, Koo JY, Krueger GG et al. Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.0% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol 2003; 48: 760-767.
19. SAS Version 8.2. SAS Institute, Cary, NC, 2003.
20. Geiger JM. Efficacy of acitretin in severe psoriasis. Skin Therapy Lett 2003; 8: 1-3.
21. Murray HE, Anhalt AW, Lessard R et al. A 12-month treatment of severe psoriasis with acitretin: Results of a Canadian open multicenter trial. J Am Acad Dermatol 1991; 24: 598-602.
22. Kragballe K, Jansén CT, Geiger JM et al. A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study. Acta Derm Venereol 1989; 69: 35-40.
23. Vahlquist C, Michaelson G, Vessby B. Serum lipoproteins in middle-aged men with psoriasis. Acta Derm Venereol 1987; 67: 12-15.
24. Vahlquist C, Selinus I, Vessby B. Serum lipids changes during acitretin (etretin) treatment of psoriasis and palmo-plantar pustulosis. Acta Derm Venereol 1988; 6: 300-305.
25. Piskin S, Gurkok F, Ekuklu G et al. Serum lipids in psoriasis. Yonsei Med J 2003; 44: 24-26.
26. Verfaille CJ, Coel M, Boersma Y et al. Oral R115866 in the treatment of moderate to severe facial acne vulgaris: An exploratory study. Br J Dermatol 2007; in press.
27. Mallbris L, Granath F, Hamsten A, Stahle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006; 54: 614-620.
28. Kurlandsky SB, Gamble MV, Ramakrishnan R et al. Plasma delivery of retinoic acid to tissues in the rat. J Biol Chem 1995; 270: 17850-17857.
29. Allen JG, Bloxham DP. The pharmacology and pharmacokinetics of the retinoids. Pharmacol Ther 1989; 40: 1-27.
30. David M, Hodak E, Lowe NJ. Adverse effects of retinoids. Med Toxicol 1988; 3: 273-288.
31. Duell EA, Kang S, Voorhees JJ. Retinoic acid isomers applied to human skin in vivo each induce a 4-hydroxylase that inactivates only trans retinoic acid. J Invest Dermatol 1996; 106: 316-320.
32. Geiger JM, Baudin M, Saurat JH. Teratogenic risk with etretinate and acitretin treatment. Dermatology 1994; 189: 109-116.
33. Bovenschen HJ, Otero ME, Langewouters AM et al. Oral retinoic acid metabolism blocking agent rambazole for plaque psoriasis: An immunohistochemical study. Br J Dermatol 2006: Accepted.
34. Cools M, Pavez-Lorie E, Borgers M et al. Effect of topical R115866 (Rambazole™) gel on the expression of biomarkers in the skin of healthy volunteers. J Invest Dermatol 2006; 126: S40 (#240).